Cargando…
Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects
Coronavirus virus disease 2019 (COVID-19) is a viral infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), actually considered as a global pandemic. The entry-point for SARS-CoV-2 is angiotensin converting enzyme 2 (ACE2) and dipeptidyl peptidase 4 (DPP4), wh...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955803/ https://www.ncbi.nlm.nih.gov/pubmed/33727066 http://dx.doi.org/10.1016/j.pupt.2021.102008 |
_version_ | 1783664316670541824 |
---|---|
author | Al-kuraishy, Hayder M. Al-Gareeb, Ali I. Qusty, Naeem Cruz-Martins, Natália El-Saber Batiha, Gaber |
author_facet | Al-kuraishy, Hayder M. Al-Gareeb, Ali I. Qusty, Naeem Cruz-Martins, Natália El-Saber Batiha, Gaber |
author_sort | Al-kuraishy, Hayder M. |
collection | PubMed |
description | Coronavirus virus disease 2019 (COVID-19) is a viral infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), actually considered as a global pandemic. The entry-point for SARS-CoV-2 is angiotensin converting enzyme 2 (ACE2) and dipeptidyl peptidase 4 (DPP4), which are highly expressed in the lung. Among other complications, COVID-19leads to fatal pneumonia, acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) due to development of cytokine storm (CS). The pathogenesis of SARS-CoV-2 infection depends on the viral load and human innate/adaptive immune response that are required for viral elimination in the first phase of COVID-19. However, an exaggerated immune response in the second phase of COVID-19 results in immune overreaction and CS-induced ALI and ARDS. Thus, in view of these considerations, we report here a series of five patients with COVID-19 pneumonia who developed ALI. In addition to the supportive therapy, the patients received doxycycline in the first week and doxycycline plus colchicine in the second week. Following sequential therapy with doxycycline and/or colchicine in patients with COVID-19 pneumonia, the patients had reduction of disease severity and symptoms with better clinical and radiological outcomes. However, it is tough to confirm the link between this therapeutic combination and recovery from COVID-19 pneumonia, as it is a small case-series report. Nevertheless, this study gives a rational for large-scale prospective studies to evaluate the dual sequential effect of doxycycline and colchicine on the COVID-19 severity. This case-series illustrated that use of colchicine: doxycycline combination is linked with marked improvements in the clinical, laboratory and radiological outcomes in patients with COVID-19 pneumonia. However, we cannot sketch any definitive conclusion from our observation, despite we hypothesize that this combination therapeutic regimen may attenuate and treat COVID-19. Further, namely prospective, randomized, and controlled clinical studies are recommended in this regard. |
format | Online Article Text |
id | pubmed-7955803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79558032021-03-15 Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects Al-kuraishy, Hayder M. Al-Gareeb, Ali I. Qusty, Naeem Cruz-Martins, Natália El-Saber Batiha, Gaber Pulm Pharmacol Ther Article Coronavirus virus disease 2019 (COVID-19) is a viral infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), actually considered as a global pandemic. The entry-point for SARS-CoV-2 is angiotensin converting enzyme 2 (ACE2) and dipeptidyl peptidase 4 (DPP4), which are highly expressed in the lung. Among other complications, COVID-19leads to fatal pneumonia, acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) due to development of cytokine storm (CS). The pathogenesis of SARS-CoV-2 infection depends on the viral load and human innate/adaptive immune response that are required for viral elimination in the first phase of COVID-19. However, an exaggerated immune response in the second phase of COVID-19 results in immune overreaction and CS-induced ALI and ARDS. Thus, in view of these considerations, we report here a series of five patients with COVID-19 pneumonia who developed ALI. In addition to the supportive therapy, the patients received doxycycline in the first week and doxycycline plus colchicine in the second week. Following sequential therapy with doxycycline and/or colchicine in patients with COVID-19 pneumonia, the patients had reduction of disease severity and symptoms with better clinical and radiological outcomes. However, it is tough to confirm the link between this therapeutic combination and recovery from COVID-19 pneumonia, as it is a small case-series report. Nevertheless, this study gives a rational for large-scale prospective studies to evaluate the dual sequential effect of doxycycline and colchicine on the COVID-19 severity. This case-series illustrated that use of colchicine: doxycycline combination is linked with marked improvements in the clinical, laboratory and radiological outcomes in patients with COVID-19 pneumonia. However, we cannot sketch any definitive conclusion from our observation, despite we hypothesize that this combination therapeutic regimen may attenuate and treat COVID-19. Further, namely prospective, randomized, and controlled clinical studies are recommended in this regard. Elsevier Ltd. 2021-04 2021-03-14 /pmc/articles/PMC7955803/ /pubmed/33727066 http://dx.doi.org/10.1016/j.pupt.2021.102008 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Al-kuraishy, Hayder M. Al-Gareeb, Ali I. Qusty, Naeem Cruz-Martins, Natália El-Saber Batiha, Gaber Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects |
title | Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects |
title_full | Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects |
title_fullStr | Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects |
title_full_unstemmed | Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects |
title_short | Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects |
title_sort | sequential doxycycline and colchicine combination therapy in covid-19: the salutary effects |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955803/ https://www.ncbi.nlm.nih.gov/pubmed/33727066 http://dx.doi.org/10.1016/j.pupt.2021.102008 |
work_keys_str_mv | AT alkuraishyhayderm sequentialdoxycyclineandcolchicinecombinationtherapyincovid19thesalutaryeffects AT algareebalii sequentialdoxycyclineandcolchicinecombinationtherapyincovid19thesalutaryeffects AT qustynaeem sequentialdoxycyclineandcolchicinecombinationtherapyincovid19thesalutaryeffects AT cruzmartinsnatalia sequentialdoxycyclineandcolchicinecombinationtherapyincovid19thesalutaryeffects AT elsaberbatihagaber sequentialdoxycyclineandcolchicinecombinationtherapyincovid19thesalutaryeffects |